Evaluation of the Efficacy and Safety of Dienogest in the Treatment of Primary Dysmenorrhea: A Study in a District-Level Hospital in Bangladesh
article
OA: diamond
CC0
Abstract
Background: Dysmenorrhea is a common symptom secondary to various gynecological disorders, but it is also represented in most women as a primary form of disease. Pain associated with dysmenorrhea is caused by hypersecretion of prostaglandins and an increased uterine contractility. The primary dysmenorrhea is quite frequent in young women and remains with a good prognosis, even though it is associated with low quality of life. Objectives: The aim of this study is to evaluate of the efficacy and safety of dienogest in the treatment of primary dysmenorrhea: a study in a district-level hospital in Bangladesh. Methods: The cross-sectional observational study was conducted in the Department of Gynae and Obs, Naogaon Sadar Hospital from July 2022 to June 2023. A total of 100 subjects who received DNG (1 mg/day, orally) were included in the study. Data were collected by face-to-face interview and analyzed by appropriate computer based programmed software Statistical Package for the Social Sciences (SPSS), version 24. Results: In this study, most of the patients 43% lies between 21 years to 25 years and body weight of 24% patients were between 51 to 55 kg. In this study, most of the patients 41% body mass index were 18.5 – 24.9 kg/m2. Most of the patients’ clinical symptoms were cramping pain in the lower abdomen (89%), low back pain (86%), pain spreading down to the leg (73%), fatigue (64%). About (56%) adverse effects were body weight gain and irregular uterine bleeding occurred in 35 of 100 cases (35%). Conclusion: Primary dysmenorrhea is one of the most common illnesses in women of childbearing age. When severe, it may interfere with the activities of daily living and may lead to school and work absenteeism. Primary dysmenorrhea is also one of the most underdiagnosed diseases, so clinicians should suspect the diagnosis in a timely manner and provide appropriate treatment.
My notes (saved in your browser only)
Condition tags
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (4)
- Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial 2008
- Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study 2017
- Dysmenorrhea, Absenteeism from School, and Symptoms Suspicious for Endometriosis in Adolescents 2014
- ACOG Practice Bulletin No. 51. Chronic pelvic pain. 2004
References (33)
- ACOG Practice Bulletin No. 51. Chronic pelvic pain. via openalex
- Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial via openalex
- Dysmenorrhea, Absenteeism from School, and Symptoms Suspicious for Endometriosis in Adolescents via openalex
- Evaluation of the efficacy and safety of dienogest in the treatment of painful symptoms in patients with adenomyosis: a randomized, double-blind, multicenter, placebo-controlled study via openalex
- doi:10.1152/ajpendo.1999.277.6.e1013 via openalex
- doi:10.1016/j.jpag.2010.02.009 via openalex
- doi:10.1002/14651858.cd002120.pub2 via openalex
- doi:10.1186/1471-2458-6-177 via openalex
- doi:10.1111/j.1447-0578.2007.00189.x via openalex
- doi:10.1001/archpedi.154.12.1226 via openalex
- doi:10.1016/j.jpain.2008.07.002 via openalex
- doi:10.15713/ins.jcri.112 via openalex
- W2417198086 via openalex
- W2547967660 via openalex
- W6666686299 via openalex
- W6678825344 via openalex
- W6679023005 via openalex
- W7073832294 via openalex
- doi:10.2147/ijwh.s112768 via openalex
- doi:10.1136/bmj.332.7550.1134 via openalex
- doi:10.1111/j.1471-0528.2004.00090.x via openalex
- doi:10.1016/s0140-6736(99)11159-0 via openalex
- doi:10.1111/j.1471-0528.2004.00012.x via openalex
- doi:10.3109/03009730903457218 via openalex
- doi:10.1093/humupd/dmv039 via openalex
- doi:10.1016/j.ijgo.2009.07.031 via openalex
- doi:10.1093/humrep/der417 via openalex
- doi:10.1016/j.jadohealth.2008.07.018 via openalex
- doi:10.1053/beog.1999.0018 via openalex
- doi:10.1016/j.ijgo.2009.09.018 via openalex
- doi:10.1111/j.1471-0528.2009.02407.x via openalex
- doi:10.1111/j.1471-0528.2006.00874.x via openalex
- doi:10.1016/s1701-2163(16)30395-4 via openalex
Source provenance
- openalex
- last seen: 2026-05-11T03:23:35.768659+00:00
License: CC0
· commercial use OK